Literature DB >> 27381389

Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.

Uyen T Dang1, Idalia Zamora1, Kirk E Hevener2, Sudip Adhikari1, Xiaoqian Wu3, Julian G Hurdle4.   

Abstract

We characterized clinically occurring and novel mutations in the β subunit of RNA polymerase in Clostridium difficile (CdRpoB), conferring rifamycin (including rifaximin) resistance. The Arg505Lys substitution did not impose an in vitro fitness cost, which may be one reason for its dominance among rifamycin-resistant clinical isolates. These observations were supported through the structural modeling of CdRpoB. In general, most mutations lacked in vitro fitness costs, suggesting that rifamycin resistance may in some cases persist in the clinic.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27381389      PMCID： PMC4997883          DOI： 10.1128/AAC.01137-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

Authors:  A J O'Neill; T Huovinen; C W G Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.

Authors:  Kevin W Garey; Zhi-Dong Jiang; Angelle Bellard; Herbert L Dupont
Journal:  J Clin Gastroenterol       Date:  2009-01       Impact factor: 3.062

3.  Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

Authors:  Jamie S Huang; Zhi-Dong Jiang; Kevin W Garey; Todd Lasco; Herbert L Dupont
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

4.  Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Eileen Ingham; Colin Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

Authors:  Stuart Johnson; Christopher Schriever; Minerva Galang; Ciarán P Kelly; Dale N Gerding
Journal:  Clin Infect Dis       Date:  2007-02-02       Impact factor: 9.079

6.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Authors:  Scott R Curry; Jane W Marsh; Kathleen A Shutt; Carlene A Muto; Mary M O'Leary; Melissa I Saul; A William Pasculle; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

7.  Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

Authors:  Philip T Cherian; Xiaoqian Wu; Lei Yang; Jerrod S Scarborough; Aman P Singh; Zahidul A Alam; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2015-08-18       Impact factor: 5.790

8.  Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection.

Authors:  X Wu; M Z Alam; L Feng; L S Tsutsumi; D Sun; J G Hurdle
Journal:  J Appl Microbiol       Date:  2014-01       Impact factor: 3.772

9.  The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.

Authors:  Xiaoqian Wu; Julian G Hurdle
Journal:  Can J Microbiol       Date:  2014-03-06       Impact factor: 2.419

Review 10.  Small animal models for the study of Clostridium difficile disease pathogenesis.

Authors:  Melanie L Hutton; Kate E Mackin; Anjana Chakravorty; Dena Lyras
Journal:  FEMS Microbiol Lett       Date:  2014-01-07       Impact factor: 2.742
View more
  6 in total

Review 1.  Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Authors:  Chetna Dureja; Abiola O Olaitan; Julian G Hurdle
Journal:  Curr Opin Microbiol       Date:  2022-01-22       Impact factor: 7.584

2.  Insights into RNA polymerase catalysis and adaptive evolution gained from mutational analysis of a locus conferring rifampicin resistance.

Authors:  Olga Yurieva; Vadim Nikiforov; Vadim Nikiforov; Michael O'Donnell; Arkady Mustaev
Journal:  Nucleic Acids Res       Date:  2017-11-02       Impact factor: 16.971

3.  Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.

Authors:  Sarah A Kuehne; Andrew W Dempster; Mark M Collery; Nimitray Joshi; Jamie Jowett; Michelle L Kelly; Rory Cave; Chris M Longshaw; Nigel P Minton
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

4.  Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014-2015.

Authors:  Brian R Kullin; Sharon Reid; Valerie Abratt
Journal:  Afr J Lab Med       Date:  2018-12-06

5.  A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile.

Authors:  Korakrit Imwattana; César Rodríguez; Thomas V Riley; Daniel R Knight
Journal:  Microb Genom       Date:  2021-11

Review 6.  Mechanisms of antibiotic resistance of Clostridioides difficile.

Authors:  Ishani Wickramage; Patrizia Spigaglia; Xingmin Sun
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.758
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.